UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF ~~THE~~

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~February~~March 261, 2013

BIOMIMETIC THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware

000-51934

62-1786244

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

389 Nichol Mill Lane, Franklin, Tennessee 37067

(Address of Principal Executive Offices) (Zip Code)

(615) 844-1280

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5 2.0701 ~~Submission~~Completion of ~~Matters~~Acquisition toor aDisposition ~~Vote~~ of ~~Security~~Assets. ~~Holders~~

On ~~February~~March 261, 2013, ~~BioMimetic~~ ~~Therapeutics,~~pursuant ~~Inc. (“BioMimetic”) held a special meeting of its stockholders (the “Special Meeting”). Two proposals were voted on at the meeting: (1)~~ to ~~adopt~~an ~~the~~ Agreement and Plan of Merger, dated as of November 19, 2012 (the “Merger Agreement”), by and ~~among~~ ~~Wright~~among ~~Medical~~BioMimetic ~~Group~~Therapeutics, Inc. (“BioMimeteic”), ~~Achilles~~Wright ~~Merger~~Medical ~~Subsidiary~~Group, Inc. (“Wright”), Achilles Acquisition Subsidiary, ~~LLC~~Inc. ~~and~~(“Merger ~~BioMimetic,~~Sub”) ~~pursuant~~and ~~to which~~ Achilles ~~Merger~~Acquisition Subsidiary, ~~Inc.~~LLC ~~will~~(“Sister beSubsidiary”), Merger Sub merged with and into BioMimetic ~~and~~with ~~immediately~~BioMimetic ~~thereafter~~as the surviving corporation (the “Initial Surviving Corporation”) of the merger (the “Merger”), followed by BioMimetic ~~will~~merging ~~merge~~ with and into ~~Achilles~~Sister ~~Acquisition~~ Subsidiary, ~~LLC~~with Sister asSubsidiary ~~described~~continuing inas the ~~definitive~~final ~~proxy~~surviving ~~statement~~entity ~~first~~(the ~~mailed~~“Final toSurviving ~~the~~Entity”) ~~stockholders of~~and ~~BioMimetic~~changing onits orname ~~about~~to ~~January~~BioMimetic 23Therapeutics, ~~2013~~LLC (the “~~Proxy~~Subsequent ~~Statement~~Merger”); and ~~(2) to approve~~, ontogether anwith ~~advisory~~the ~~(non-binding) basis~~Merger, the “~~golden parachute~~Mergers”). BioMimetic ~~compensation~~stockholders ~~payments~~adopted ~~that~~the ~~will~~Merger orAgreement ~~may~~at bea ~~paid~~special bymeeting of BioMimetic tostockholders ~~its~~held ~~named~~on ~~executive~~February ~~officers in~~26, ~~connection~~2013. ~~with~~Upon the ~~merger~~completion asof ~~described~~the inMergers, ~~the~~BioMimetic ~~Proxy~~Therapeutics, ~~Statement~~LLC became a wholly-owned subsidiary of Wright.

~~Stockholders~~As a result of ~~record~~ the Merger and at the ~~close~~effective time of ~~business~~the onMerger ~~January~~(the 2“Effective Time”), ~~2013~~each ~~were~~share ~~entitled~~of tocommon ~~vote~~stock, atpar value $0.001 per share, of BioMimetic (the ~~Special~~“BioMimetic ~~Meeting.~~Common AsStock”) issued and outstanding immediately prior to the Effective Time (other than treasury shares of ~~January~~BioMimetic 2,and ~~2013~~any shares of BioMimetic Common Stock owned by Wright, ~~there~~Merger Sub ~~were~~or ~~28,264,814~~any ~~shares~~wholly-owned subsidiary of ~~common~~Wright ~~stock~~or ~~outstanding~~BioMimetic), ~~and~~was ~~entitled~~converted into the right to ~~vote.~~receive A(i) ~~quorum~~an ~~consisting~~amount ~~of 14~~in cash,~~132~~ without interest,~~408~~ ~~shares~~equal to $1.50, (ii) 0.2482 of a share of common stock, par value $.01 per share, of ~~BioMimetic~~Wright ~~were~~(the ~~present~~“Wright Common orStock”), ~~represented~~and at(iii) one contingent value right (a “CVR”) issued by Wright subject to and in accordance with the ~~meeting~~Contingent Value Rights Agreement between Wright and American Stock Transfer & Trust Company, LLC, as trustee.

~~All~~At of the ~~proposals requiring~~Effective ~~approval~~Time, all outstanding stock options of BioMimetic that were ~~approved~~not exercised by the ~~requisite~~holders ~~vote~~thereof ~~necessary,~~prior to the Effective Time were assumed by Wright and ~~the~~converted ~~votes~~into ~~with~~an ~~respect~~option to ~~each~~acquire a certain number of shares of Wright Common Stock for a new exercise price, in each case, on the ~~proposals~~terms ~~are~~and ~~set~~conditions ~~forth below:~~specified in the Merger Agreement.

~~(1)~~The Toforegoing ~~adopt~~description of the ~~Agreement~~Merger and ~~Plan~~the of Merger, ~~dated~~Agreement ~~November~~does ~~19,~~not ~~2012,~~purport byto be complete and ~~among~~is ~~Wright~~qualified ~~Medical~~in ~~Group,~~its ~~Inc.,~~entirety ~~Achilles~~by reference to the Merger ~~Subsidiary~~Agreement, ~~Inc~~which was attached as Exhibit 2.,1 ~~Achilles~~to ~~Acquisition~~BioMimetic’s ~~Subsidiary~~Current Report on Form 8-K filed with Securities and Exchange Commission on November 19, ~~LLC~~2012 and ~~BioMimetic:~~is incorporated herein by reference.

For		Against		Abstain
19,899,622		175,108		26,780

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On March 1, 2013, following the completion of the Merger, BioMimetic notified The NASDAQ Global Select Market (2“NASDAQ”) Tothat the ~~approve,~~Merger was completed and requested that (i) trading of BioMimetic Common Stock on anNASDAQ ~~advisory~~be suspended and (~~non-binding~~ii) ~~basis,~~NASDAQ file with the ~~“golden~~Securities ~~parachute”~~and ~~compensation~~Exchange ~~payments~~Commission ~~that~~an ~~will~~application oron ~~may~~Form be25 ~~paid~~to bydelist and deregister BioMimetic Common Stock. BioMimetic intends to ~~its~~file ~~named~~a ~~executive~~certification ~~officers~~on inForm ~~connection~~15 ~~with~~requesting that BioMimetic’s reporting obligations under Sections 13 and 15(d) of the ~~merger:~~Securities Exchange Act of 1934, as amended, be suspended.

For		Against		Abstain
18,132,287		1,909,948		59,275

Item 3.03 Material Modification to Rights of Security Holders.

~~SIGNATURES~~The information required by Item 3.03 is contained in Item 2.01 of this Current Report on Form 8-K and is incorporated herein by reference.

~~Pursuant~~Item to5.01 ~~the~~Changes ~~requirements~~in ofControl ~~the Securities Exchange Act~~ of ~~1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~Registrant.

~~BIOMIMETIC~~In ~~THERAPEUTICS~~connection with the Merger and at the Effective Time, ~~INC~~a change of control of BioMimetic occurred and, following the name change of the Final Surviving Entity to BioMimetic Therapeutics, LLC, BioMimetic Therapeutics, LLC became a wholly-owned subsidiary of Wright. ~~By:~~A ~~/s/~~total ~~Larry~~of ~~Bullock~~approximately ~~Name:~~$42.5 ~~Larry~~million ~~Bullock~~in ~~Title:~~cash ~~Chief~~will ~~Financial~~be ~~Officer~~paid, and approximately 7.0 million shares of Wright Common Stock and 28.1 million CVRs will be issued, as consideration for the Merger.

~~Date:~~The ~~February~~information ~~26,~~contained ~~2013~~in Item 2.01 of this Current Report on Form 8-K is incorporated herein by reference.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Pursuant to the terms of the Merger Agreement, at the Effective Time, each of the then-current directors and officers of BioMimetic was removed and, at the effective time of the Subsequent Merger, the directors and officers of the Initial Surviving Corporation immediately prior to the effective time of the Subsequent Merger became the managers and officers of BioMimetic Therapeutics, LLC.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit		Description

2.1		Agreement and Plan of Merger, by and among BioMimetic Therapeutics, Inc., Wright Medical Group, Inc., Achilles Merger Subsidiary, Inc. and Achilles Acquisition Subsidiary, LLC, dated as of November 19, 2012 (incorporated by reference to Exhibit 2.1 to BioMimetic’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 19, 2012).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


BIOMIMETIC THERAPEUTICS, INC.

By:	/s/ James A. Lightman
	Name:	James A. Lightman
	Title:	Secretary

Date: March 6, 2013

Filing Compare · BIOMIMETIC THERAPEUTICS, INC.